Explanipedia

Prolonged Progression-Free Survival, Disease-Free Survival, and Cystectomy Avoidance With IL-15 Receptor Lymphocyte–Stimulating Agent NAI Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin–Unresponsive Papillary-Only Nonmuscle-Invasive Bladder Cancer Open

Sam S. Chang, Karim Chamie, Eugene V. Kramolowsky, Mark L. Gonzalgo, Piyush K. Agarwal , et al. · 2025

ClinicalTrials.gov Identifier: NCT03022825.

Aquablation therapy in large prostates (80–150 cc) for lower urinary tract symptoms due to benign prostatic hyperplasia: WATER II 3‐year trial results Open

Kevin C. Zorn, Mohamed Bidair, Andrew Trainer, Andrew Arther, Eugene V. Kramolowsky , et al. · 2021

Objective The objective of this study is to determine if Aquablation therapy can maintain its effectiveness in treating men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) with large‐volume (80–150 cc) pr…

Aquablation for benign prostatic hyperplasia in large prostates (80-150cc): 3-year results Open

Kevin C. Zorn, Mo Bidair, Naeem Bhojani, Andrew Trainer, Andrew Arther , et al. · 2021

Longitudinal follow‐up and performance validation of an mRNA‐based urine test (Xpert <sup>®</sup> Bladder Cancer Monitor ) for surveillance in patients with non‐muscle‐invasive bladder cancer Open

Barrett E. Cowan, Eric Klein, Ken Jansz, K.R. Westenfelder, Timothy Bradford , et al. · 2021

Objective To evaluate the performance of the Xpert Bladder Cancer Monitor (Xpert; Cepheid, Sunnyvale, CA, USA) test as a predictor of tumour recurrence in patients with non‐muscle‐invasive bladder cancer (NMIBC). Patients and Methods Patie…

Validation of an mRNA-based Urine Test for the Detection of Bladder Cancer in Patients with Haematuria Open

F. Johannes P. van Valenberg, Andrew M. Hiar, Ellen Wallace, Julia A. Bridge, Donna Mayne , et al. · 2020

Aquablation for benign prostatic hyperplasia in large prostates (80-150cc): 2-year results Open

Kevin C. Zorn, Mo Bidair, Andrew Trainer, Andrew Arther, Eugene V. Kramolowsky , et al. · 2020

PD56-05 THREE-YEAR OUTCOMES AFTER AQUABLATION COMPARED TO TURP: EFFICACY AND EJACULATORY IMPROVEMENTS SUSTAINED Open

P. Gilling, Neil Barber, Mo Bidair, Paul Anderson, M. R. Sutton , et al. · 2020

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Surgical Therapy & New Technology III (PD56)1 Apr 2020PD56-05 THREE-YEAR OUTCOMES AFTER AQUABLATION COMPARED TO TURP: EFFICACY AND EJACULATORY IMPROVEMENTS SUSTAINED Peter Gill…

Table of Contents Open

Naeem Bhojani, Mohamed Bidair, Kevin C. Zorn, Andrew Trainer, Andrew Arther , et al. · 2019

Aquablation for Benign Prostatic Hyperplasia in Large Prostates (80-150 cc): 1-Year Results Open

Naeem Bhojani, Mohamed Bidair, Kevin C. Zorn, Andrew Trainer, Andrew Arther , et al. · 2019

Two-Year Outcomes After Aquablation Compared to TURP: Efficacy and Ejaculatory Improvements Sustained Open

Peter Gilling, Neil Barber, Mohamed Bidair, Paul Anderson, Mark Sutton , et al. · 2019

MP73-10 CARE PATHWAY IMPLEMENTATION INFLUENCES CONVERSION TO SURGICAL THERAPY IN BPH PATIENTS Open

Andrew Trainer, Euclid DeSouza, John Horgan, Bruce Lundak, S. Bolte , et al. · 2018

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Surgical Therapy & New Technology II1 Apr 2018MP73-10 CARE PATHWAY IMPLEMENTATION INFLUENCES CONVERSION TO SURGICAL THERAPY IN BPH PATIENTS Andrew Trainer, Euclid deSouza, John…

Andrew Trainer YOU? Author Swipe